• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/9/21 4:46:37 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NVIV alert in real time by email
    SC 13G/A 1 nviv_13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934


    InVivo Therapeutics Holdings Corp.

    (Name of Issuer)

     

    Common Stock, $0.00001 par value

    (Title of Class of Securities)

     

    46186M506

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒ Rule 13d-2(b)

     

    ☐ Rule 13d-2(c)

     

    ☐ Rule 13d-2(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities and Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     




     

     

    CUSIP No.  46186M506

     

    13G

     

    Page 2 of 5 Pages

     

    1 

    NAME OF REPORTING PERSONS

     

     

     

    L1 Capital Global Opportunities Master Fund Ltd.

    2

    CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP

     

     

    (a)  ☐

     

    (b)  ☐

    3

    SEC USE ONLY

     

     

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

     

     

    Cayman Islands 

     

    5                 

    SOLE VOTING POWER

     

     

     

     

     

    1,061,250 shares of Common Stock(1)(2)

    NUMBER OF

    6

    SHARED VOTING POWER

    SHARES

     

     

    BENEFICIALLY

     

     0

    OWNED BY

    7

    SOLE DISPOSITIVE POWER

    EACH REPORTING

     

     

    PERSON WITH

     

    1,061,250 shares of Common Stock(1)(2)

     

    8

    SHARED DISPOSITIVE POWER

     

     

     

     

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     

     

     1,061,250 shares of Common Stock(1)(2)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     

     

    4.8%

    12

    TYPE OF REPORTING PERSON

     

     

    FI

     

     

     

     


    (1)

    David Feldman and Joel Arber are both the directors of L1 Capital Global Opportunities Master Fund Ltd. As such they each individually have sole dispositive and voting power.


    (2)

    The number of shares of common stock represents shares of common stock issuable apon exercise of warrants.





     

     

    CUSIP No.  46186M506

     

    13G

     

    Page 3 of 5 Pages

     

    Item 1. Security and Issuer.

     

     

    (a)

    Name of Issuer:

     

    InVivo Therapeutics Holdings Corp.

     


    (b)


    Address of Issuer:


    One Kendall Square, Suite B14402

    Cambridge, Massachusetts 02139


     

    Item 2. Identity and Background.

     

    (a) 

    Name of Person Filing:

     

     

     

    L1 Capital Global Opportunities Master Fund, Ltd.

     

     

    (b)  

    Address of Principal Business Office or, if none, Residence:

     

     

     

    161A Shedden Road, 1 Artillery Court

    PO Box 10085

    Grand Cayman, Cayman Islands KY1-1001

     

     

    (c)

    Citizenship or Place of Organization:

     

     

     

    Cayman Islands

     

     

    (d)

    Title of Class of Securities:

     

     

     

    Common Stock, $0.00001 par value

     

     

    (e) 

    CUSIP Number:

     

     

     

     46186M506  

     

    Item 3.

     

    Not applicable.

     

     




     

     

    CUSIP No. 46186M506

     

    13G

     

    Page 4 of 5 Pages

     

    Item 4. Ownership.

     

     

    (a)

    The information required by Items 4(a)-(c) is set forth in Rows (5)-(9) and Row (11) of the cover page and is incorporated herein by reference.

     

     

    (b)

    The percentage set forth on Row (11) of the cover page for the reporting person is based on 22,233,286 shares of Common Stock outstanding.

     

     

    (c)

    David Feldman and Joel Arber are the Directors of L1 Capital Global Opportunities Master Fund Ltd. As such, L1 Capital Global Opportunities Master Fund Ltd,  Mr. Feldman and Mr. Arber may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) 1,061,250 shares of Common Stock. To the extent Mr. Feldman and Mr. Arber are deemed to beneficially own such shares, Mr. Feldman and Mr. Arber disclaim beneficial ownership of these securities for all other purposes.

     

     

    (d)

    The reporting person is a beneficial owner of 1,061,250 shares of Common Stock.

     

    Item 5.

    Ownership of 5 Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ

     

    Item 6.

    Ownership of More than 5 Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.

    Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

     

     





     

    CUSIP No.  46186M506

     

    13G

     

    Page 5 of 5 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

     

     

     

    By:

    L1 Capital Global Opportunities Master Fund Ltd.

     

     

     

    February 8, 2020

    By:

    /s/ David Feldman

     

     

    David Feldman, Director

     

     

     

     

     




    Get the next $NVIV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVIV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVIV
    SEC Filings

    View All

    InVivo Therapeutics Holdings Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)

    2/6/24 8:00:33 AM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    InVivo Therapeutics Holdings Corp filed SEC Form 8-K: Bankruptcy or Receivership

    8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)

    2/1/24 8:00:41 AM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    InVivo Therapeutics Holdings Corp filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)

    1/3/24 4:30:44 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVIV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Foose Brice sold $123,030 worth of InVivo Therapeutics Holdings Corp (330,000 units at $0.37), closing all direct ownership in the company (SEC Form 4) (Amendment)

    4/A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)

    2/7/24 2:12:16 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Foose Brice closing all direct ownership in the company (SEC Form 4)

    4 - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)

    2/7/24 1:31:40 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3: New insider Foose Brice claimed ownership of 330,000 units of InVivo Therapeutics Holdings Corp

    3 - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)

    4/24/23 3:26:07 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVIV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury

    Study did not achieve primary endpoint of defined improvement on standard impairment scale InVivo to evaluate full data set and strategic options for the company InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCI), today announced topline results from the company's INSPIRE 2.0 study, which was designed to evaluate the safety and probable benefit of InVivo's investigational Neuro-Spinal Scaffold™, a bioresorbable scaffold-based device in development for patients with acute SCI. The study did not meet its primary endpoint, which was assessed by the proportion of tre

    3/9/23 8:55:00 AM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    InVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

    InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has closed its previously announced registered direct offering for the sale and issuance of 154,000 shares of the Company's common stock and pre-funded warrants to purchase up to 369,810 shares of common stock to a single healthcare-focused institutional investor. The Company also closed its previously announced private placement priced at-the-market under Nasdaq rules for the sale and issuance of pre-funded warrants to purchase up to 1,190,476 shares of common stock with the same investor in the

    10/11/22 4:01:00 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

    InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the sale and issuance of 523,810 shares of the Company's common stock (or pre-funded warrants in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. Concurrently with the registered direct offering, the Company entered into a definitive agreement with the investor in the registered direct offering for the sale and issuance of 1,190,476 shares of common stock (or

    10/7/22 8:00:00 AM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVIV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Foose Brice closing all direct ownership in the company (SEC Form 4)

    4 - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)

    2/7/24 1:31:40 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVIV
    Leadership Updates

    Live Leadership Updates

    View All

    InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel

    InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the appointment of Heather M. Hamel, J.D. as its Chief Legal Officer and General Counsel. In her role, Ms. Hamel will lead the company's legal and intellectual property functions, and provide strategic guidance to the company's Board of Directors and executive management team. Ms. Hamel will also be responsible for the oversight of certain other functions, including business development, human resources and external communications. Prior to this appointment, Ms. Hamel served as the company's Vice Preside

    7/13/22 8:30:00 AM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVIV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by InVivo Therapeutics Holdings Corp (Amendment)

    SC 13G/A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Subject)

    2/14/24 2:53:34 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by InVivo Therapeutics Holdings Corp (Amendment)

    SC 13G/A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Subject)

    2/13/24 8:09:46 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by InVivo Therapeutics Holdings Corp (Amendment)

    SC 13G/A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Subject)

    2/6/24 12:08:03 PM ET
    $NVIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care